BMY will pay BBIO $90 million in upfront cash.
The AstraZeneca deal continues to be a good one for Innate Pharma, year after year.
The company will merge with Isleworth Healthcare Acquisition Corp.
Coeptis is developing novel cell therapy platforms for cancer.
Image source: Affimed
Affimed (AFMD) announced 22,500,000 of its common shares at a public offering price of $4.00
Investment thesis
_____
Source: Equities News
...
Oxford provides senior debt to life sciences and healthcare services companies worldwide.
Sensus posted revenues of $13.0 million, up 156% over the prior year's Q4.
The appetite for next generation breast cancer therapies continues to grow unabated.
Shares of TG Therapeutics (TGTX) got slammed Thursday after CEO Michael Weiss disclosed that the FDA had placed a partial hold on the company's Phase 3 trial lost 40.5% of their value Thursday on nevaluating the investigational U2 combination (UKONIQ® (umbralisib) and ublituximab) compared to the control arm of obinutuzumab plus chlorambucil and that the FDA imposed a partial clinical hold on select studies of U2 and its components for chronic lymphocytic leukemia (CLL) ...
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
